rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

NovaBridge Biosciences - American Depositary Shares

NBP · Nasdaq

Health CareBiotechnologyNot moving yet

NBP stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 24.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 38
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$1.2M
Insider sales, 12 months
$309K
Officials’ trades on record
0
Institutions holding
48 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months7
Buyers · sellers1 · 3
WhoDidSharesTraded
Phillip Andrew DennisChief Medical Officersold8,209at $0.7118 Sep 2026filed 21 Sep 2026
Sean Wuxiong CaoChief Bus. Development Officersold107,978at $0.749 Sep 2026filed 11 Sep 2026
Cong Claire XuEVP, Clinical Developmentsold3,282at $0.7931 Aug 2026filed 1 Sep 2026
Cong Claire XuSVP, Clinical Developmentsold4,485at $0.896 Jul 2026filed 7 Jul 2026
Phillip Andrew DennisChief Medical Officersold8,494at $0.6618 Jun 2026filed 22 Jun 2026
Cong Claire XuSVP, Clinical Developmentsold3,494at $3.941 Jun 2026filed 2 Jun 2026
Sean Wuxiong CaoDirector, Officersold21,399at $1.9914 May 2026filed 18 May 2026
Mark Arnold HaglerOfficerbought230,000at $2.5124 Apr 2026filed 28 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders48+3 on the quarter
New · exited13 · 10
Reported value$48.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
HHLR ADVISORS, LTD.unchanged · filed 14 Aug 20265,980,568$11.7M00.0%
MORGAN STANLEYreduced · filed 13 Aug 20263,653,228$7.1M-184,970−4.8%
AIHC Capital Management Ltdadded · filed 13 Aug 20262,878,033$5.6M+615,100+27.2%
Siren, L.L.C.reduced · filed 13 Aug 20262,004,739$3.9M-995,261−33.2%
MARSHALL WACE, LLPnew · filed 13 Aug 20261,231,946$2.4M+1,231,946
Candriam S.C.A.unchanged · filed 13 Aug 20261,132,563$2.2M00.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 20261,000,000$1.9M00.0%
TWO SIGMA INVESTMENTS, LPnew · filed 14 Aug 2026851,348$1.7M+851,348
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026758,226$1.5M+485,814+178.3%
BlackRock, Inc.added · filed 7 Aug 2026686,208$1.3M+58,712+9.4%
31 Mar 2023 – 30 Jun 2026
254054Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Ian Ying Woo Company insiderDirector · last 15 Oct 20260 · 0
Phillip Andrew Dennis Company insiderChief Medical Officer · last 18 Sep 20260 · 2
Sean Wuxiong Cao Company insiderChief Bus. Development Officer · last 9 Sep 20260 · 2
Cong Claire Xu Company insiderEVP, Clinical Development · last 31 Aug 20260 · 3
Robert A. Lenz Company insiderDirector · last 22 Aug 20260 · 0
Liwei Lorraine Lin Company insiderGeneral Counsel · last 8 Jul 20260 · 0
Mark Arnold Hagler Company insiderChief Commercial Officer · last 8 Jul 20261 · 0
Srishti Gupta Company insiderChief Executive Officer · last 6 Jul 20260 · 0
Wei Fu Company insiderDirector · last 29 Jun 20260 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-40.4%
Share count trendFY 2025 · to 31 Dec 202541.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$210.6M
Free cash flowFY 2025 · to 31 Dec 2025−$20.6M

Analyst forecasts

No analyst forecasts yet.